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Abstract 
Background: Unintentional weight loss is a hallmark of 
frailty and is associated with poor outcomes in older adults 
with type 2 diabetes. As such, the role of pharmacological 
therapies that facilitate weight loss – namely, sodium-         
glucose co-transporter-2 (SGLT-2) inhibitors and glucagon-
like peptide-1 (GLP-1) receptor agonists – remains uncertain 
in fitter older adults. We performed a systematic review and 
meta-analysis to evaluate these agents on major adverse      
cardiovascular events (MACE) in older adults eligible for par-
ticipation in cardiovascular outcome trials.  
Methods: A literature search was performed in MEDLINE, 
EMBASE, CINAHL, Cochrane Central Registry of Controlled 
Trials (CENTRAL) and CNKI from inception to 29 June 2020. A 
class-specific meta-analysis was conducted in older adults 
(>65 years at recruitment) and compared with the similar 
analysis in younger (<65 years) adults.       
Results: Of 761 unique studies identified, nine met the crite-
ria for inclusion, five using GLP-1 receptor agonists and four 
with SGLT-2 inhibitors. GLP-1 receptor agonists in older 
adults were associated with a 15.3% (OR 0.847 (95% CI 0.788 
to 0.910)) reduction in MACE events, similar to the 16% ben-
efit seen in younger adults. The use of SGLT-2 inhibitors          
reduced MACE in older participants by 16.9% (OR 0.831 (95% 
CI 0.699 to 0.989)), numerically superior to the impact in 
younger patients (OR 0.936 (95% CI 0.787 to 1.113).     
Conclusions: GLP-1 receptor agonists and SGLT-2 inhibitors 
reduced MACE outcomes in older adults who were eligible 
to participate in clinical trials. Whereas this is reassuring for 
the biologically robust, it should not be extrapolated to frail 
older adults without further investigation.    
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Introduction 
The International Diabetes Federation estimated the number of 
people living with diabetes worldwide at 463 million in 2019, 
85% of whom had type 2 diabetes.1 This figure, however, does 
not include adults over the age of 80. In the UK, approximately 
20% of the population over the age of 85 have diabetes and 
27% of people in care homes, accounting for 15% of the British 
population living with diabetes.2      
Frailty – that is, a reduction in physiological reserve with asso-
ciated sarcopenia, weight loss and functional decline – is a recog-
nised complication of diabetes. Older adults with frailty and 
diabetes are at a greater risk from medication side effects, 
polypharmacy and complications due to their co-morbidities.2 
There has been a recent focus on addressing the over-treatment 
of frail older adults in order to reduce this risk after the publication 
of a national stakeholders document for the assessment and        
target setting,3 followed by the adoption of this standard by the 
National Institute for Health and Care Excellence (NICE; NG158 
and NG160) and the General Medical Services Quality Outcome 
Framework (GMS QOF) for primary care. Within these guidance 
documents, the use of drugs that promote weight loss are dis-
couraged as a potential risk for progression of frailty. Specifically, 
the use glucagon-like peptide-1 (GLP-1) receptor agonists and 
sodium-glucose co-transporter-2 (SGLT-2) inhibitors are high-
lighted as agents that may carry risk for older adults. It is impor-
tant to remember, however, that the majority of older adults are 
not frail. This was recognised in the stakeholders guidance docu-
ment, which recommended that biologically fit older adults living 
with diabetes should be treated in a similar manner to their 
chronologically younger counterparts.3 Notwithstanding this, 
there remain concerns among some healthcare workers that 
agents facilitating weight loss may augment progression to frailty. 
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GLP-1 analogues mimic the incretin response to food, increas-
ing insulin secretion, slowing gastric emptying and promoting sati-
ety.4 In the younger population (<65 years of age) these are 
associated with approximately 4–6 kg weight loss.5 SGLT-2 in-
hibitors reduce glucose reabsorption in the proximal tubule of the 
nephron, thereby promoting calorie loss and producing a similar 
4–6 kg weight loss.6 These medications have been proven to        
reduce the incidence of major adverse cardiac events (MACE;      
cardiovascular death, non-fatal myocardial infarction and non-
fatal stroke) in high-risk trial populations with type 2 diabetes.7 
We planned to address the uncertainty as to whether these 
agents have similar cardiovascular benefits in older patients as is 
accepted in younger populations, or whether the impact on 
weight loss promotes frailty thereby failing to show benefit or 
even being associated with harm. We performed a systematic re-
view and meta-analysis of cardiovascular outcome trials of GLP-1 
receptor agonists and SGLT-2 inhibitors, where a priori or post hoc 
analyses were presented stratified by age.    
        
Methods 
The protocol is registered on the PROSPERO database 
(CRD42020200601) and is reported in accordance with the report-
ing guidance provided in the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses Protocols (PRISMA-P) statement.8,9  
 
Eligibility criteria 
Studies were selected according to the following criteria: 
• Study design: Only prospective randomised controlled trials 
were included. Retrospective comparative cohort studies, 
case–control or nested case–control studies and case series 
were excluded. 
• Participants: Any study that included people with type 2 di-
abetes and presented an a priori or post hoc age-stratified 
analysis with an event rate reported for ‘older adults’. Any 
age ≥65 years was regarded as satisfactory for ‘older’.  
• Interventions: Studies that used a GLP-1 receptor antagonist 
or SGLT-2 inhibitor as the agent of interest. 
• Comparators: The comparator could be placebo or standard 
care management aiming for glycaemic equipoise. 
• Outcome measures: Adjudicated MACE outcome was re-
quired. This could be a 3-point MACE (cardiovascular death, 
non-fatal myocardial infarction or non-fatal stroke), a 4-point 
MACE (3-point plus hospitalisation for acute coronary syn-
drome) or MACE+ (3- or 4-point MACE and hospitalisation 
for heart failure). 
 
Information sources and search strategy 
We searched the following electronic databases: MEDLINE,      
EMBASE, CINAHL, Cochrane Central Registry of Controlled Trials 
(CENTRAL) and CNKI from inception to 29 June 2020. Only En-
glish language manuscripts were included. The reference lists of 
included studies were also searched for additional studies.  
 
Screening, selection and data extraction procedure 
Both authors screened all articles identified from the search       
independently, starting with titles and abstracts and then full 
texts were examined in detail. Any disagreements would have 
been resolved by discussion; however, both authors reached con-
sensus on first review.  
 
Risk of bias assessment 
All studies were assessed for risk of bias (ROB) using the 
Cochrane ROB 2.0 tool in five domains: bias arising from the 
randomisation process, due to deviations from intended inter-
ventions, due to missing outcome data, in the measurement of 
the outcome and in the selection of the reported result.10 The 
signalling questions were judged as yes, probably yes, probably 
no, no, or no information, resulting in an overall judgement of 
study ROB as high, uncertain or low. 
 
Data synthesis and additional analyses 
Study characteristics are presented in a summary of characteris-
tics table. Pooled estimates using the random-effects model, 
which is a more conservative estimate of treatment effect, were 
calculated for all treatments combined, then stratified for SGLT-
2 inhibitors and GLP-1 receptor agonists. All analyses were per-
formed using OpenMeta software. Heterogeneity was quantified 
by estimating the variance between studies using the I2 statistic.  
 
Results 
After duplications were removed, our initial search identified a 
possible 761 publications. The initial screen of abstracts reduced 
this to 103 manuscripts which were reviewed in full (Figure 1). 
Nine studies met our inclusion criteria, five using GLP-1 receptor 
agonists and four using SGLT-2 inhibitors. Descriptive details of 
Figure 1. PRISMA flow chart 
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for eligibility 
(n=103)
Full-text articles excluded 
with reasons 
(n=95)
Studies included in 
systematic review 
(n=8)
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these studies are presented in Tables 1 and 2. One notable study 
that could not be incorporated was the ELIXA (Lixisenatide in    
Patients with Type 2 Diabetes and Acute Coronary Syndrome) 
trial which did not report any age-specific findings.11 
 
Glucagon-like peptide-1 (GLP-1) receptor agonists 
There were five placebo randomised controlled trials of subcu-
taneously administered GLP-1 receptor agonists, all in addition 
to standard of care including optimisation of blood pressure and 
lipid control. Four were post-marketing cardiovascular safety 
studies that allowed escalation of non-incretin-based therapy in 
order to match glycaemic control (EXSCEL using exenatide,12 
LEADER using liraglutide,13 HARMONY using albiglutide14 and 
REWIND using dulaglutide15) with a trial duration ranging from 
1.8 to 5.4 years. SUSTAIN-6 testing semaglutide was a placebo-
controlled pre-approval regulatory study with a shorter duration 
and no a priori plan to achieve glycaemic equipoise.16 There were 
differing proportions of those with pre-existing cardiovascular 
disease compared with those at high cardiovascular risk in these 
trials; however, all studies were well balanced through randomi-
sation (Table 1). Of these studies, EXSCEL16 achieved the primary 
endpoint of non-inferiority compared with placebo whereas 
those using GLP-1 analogues (ie, liraglutide, albiglutide, dulaglu-
tide and semaglutide) demonstrated superiority compared with 
placebo in reducing cardiovascular events. These studies used a 
nominal cut-off for ‘elderly’ of ≥60, ≥65 and/or ≥75 years. In the 
case of EXSCEL and HARMONY, there were dual cut-offs with 
65–75 and ≥75 years being reported separately. In total there 
were 25,219 older adults in these studies, with 1,604 events in 
those on treatment compared with 1,880 in the placebo group 
(OR 0.847 (95% CI 0.788 to 0.910), test for heterogeneity 
I2=0%, p=0.7; Figure 2A). The absolute risk reduction was 
1.94% with a number needed to treat of 51.5 over 3.3 years to 
prevent a MACE. There was a numerically similar 16% benefit 
in the younger participants in the studies (OR 0.840 (95% CI 
0.698 to 1.011); Figure 3A), although this was not statistically 
significant despite exploring outcomes in a similar number of 
patients (n=22,824). There was, however, significant hetero-
geneity in the results of the younger adults, (I2=73%, p=0.005), 
such that the EXSCEL study was to the right of the line of unity 
demonstrating a point estimate in favour of placebo with confi-
dence intervals crossing 1. The absolute risk reduction among 
the agents in younger adults was 0.94%, requiring a number 
needed to treat of 106 participants to prevent one event. 
 
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors 
Four studies met our a priori selection criteria; however, one 
study (The Canagliflozin and Cardiovascular and Renal Events in 
Type 2 Diabetes; The CANVAS program) reported their findings 
in events per 1,000 patient years rather than absolute numbers, 
REVIEW
Table 1 Placebo-controlled trials of glucagon-like peptide-1 receptor agonists that reported 3-point MACE outcomes in older adults  
 
Trial Year Number Drug ‘Older’ Drug Placebo Hazard 95% CI % 
of age events events ratio established 
participants CV disease 
 
LEADER 2016 9340 Liraglutide 60 468/3471 528/3548 0.90 0.79 to 1.02 81 
 
SUSTAIN-6 2016 3297 Semaglutide 65 55/793 76/805 0.72 0.51 to 1.02 83 
 
EXSCEL 2017 14752 Exenatide 65 426/2964 512/2975 0.80 0.71 to 0.91 73 
 
75 120/609 145/641 0.82 0.64 to 1.05  
 
Harmony 2018 9463 Albiglutide 65-74 154/1771 166/1838 0.97 0.78 to 1.21 100 
 
75 50/575 69/565 0.69 0.48 to 1.00  
 
REWIND 2019 9901 Dulaglutide 66 331/2314 384/2350 0.86 0.74 to 1.00 31 
Table 2 Placebo-controlled trials of sodium-glucose co-transporter-2 inhibitors that reported 3-point MACE outcomes in older adults  
 
Trial Year Number Drug ‘Older’ Drug Placebo Hazard 95% CI % 
of age events events ratio established 
participants CV disease 
 
Empa-REG 2015 7020 Empagliflozin 65 239/2091 161/1036 0.71 0.59 to 0.87 100 
 
CANVAS* 2017 10142 Canagliflozin 65 33.8/1000 42.3/1000 0.80 0.67 to 0.95 66 
 
DECLARE 2019 17160 Dapagliflozin 65 390/3951 418/3956 0.927 0.801 to 1.072 41 
 
CREDENCE 2019 4401 Canagliflozin 65 120/1009 143/1048 0.85 0.67 to 1.09 50  
 
*The CANVAS programme reported events per 1000 patient years therefore, although point estimates can be calculated, these data did not contribute 
to the meta-analysis. 
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rendering it impossible to include these data in the meta-analy-
sis.17 The findings from CANVAS are therefore presented in the 
summary in Table 2, but not in the meta-analysis (Figure 2B).  
The remaining three studies explored the role of em-
pagliflozin after an acute coronary event (EMPA-REG),18 da-
pagliflozin in those with established or at high risk of developing 
cardiovascular disease (DECLARE)19 and canagliflozin in renal im-
pairment (estimated glomerular filtration rate (eGFR) 30–90 
mL/min; CREDENCE).20 All studies were placebo controlled in     
addition to standard of care with the intention of achieving gly-
caemic equipoise and met their primary endpoint of cardiovas-
cular safety. EMPA-REG and CREDENCE achieved superiority 
compared with placebo in the total population whereas, in       
DECLARE, dapagliflozin only achieved the latter of the two       
REVIEW
Figure 2. Major adverse cardiovascular events (MACE) in placebo-controlled trials comparing (A) glucagon-like peptide-1 receptor 
agonists (GLP-1RA) and (B) sodium-glucose co-transporter-2 inhibitors (SGLT-2i) in addition to standard of care in older 
adults (>65 years). 
Figure 3. Major adverse cardiovascular events (MACE) in placebo-controlled trials comparing (A) glucagon-like peptide-1 receptor 
agonists (GLP-1RA) and (B) sodium-glucose co-transporter-2 inhibitors (SGLT-2i) in addition to standard of care in older 
adults (>65 years). 
(A)
Studies 
LEADER >65 year old 2016 
SUSTAIN-6 >65 year old 2016 
EXSCEL >65 year old 2017 
HARMONEY >65 year old 2018 
REWIND >65 year old 2019 
Overall (I^2=0%, p=0.746)
1.40.8 0.850.4
Odds ratio (log scale)
Estimate (95% CI) 
0.891 (0.779, 1.019) 
0.715 (0.498, 1.026) 
0.812 (0.717, 0.920) 
0.875 (0.718, 1.065) 
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endpoints from the split alpha between 3-point MACE and hos-
pitalisations due to heart failure. 
In combination, there were 13,091 older adults considered 
in the analysis of the SGLT-2 inhibitors (Figure 2B). The 749 
events in the 7,051 individuals in the treatment group (10.62%) 
was superior to the 722 events in the 6,040 individuals in the 
placebo group (11.95%) by 17% (OR 0.831 (95% CI 0.699 to 
0.989): test for heterogeneity I2=54.8%, p=0.11). This absolute 
risk reduction of 1.33% translates to a number needed to treat 
of 75 people for 3.5 years to prevent one cardiovascular event. 
This compares favourably to younger patients in whom there 
was a non-significant 0.2% absolute risk reduction (OR 0.936 
(95% CI 0.787 to 1.113); Figure 3B). Of interest, the point esti-
mates of CANVAS program for both older (OR 0.80 (95% CI 
0.67 to 0.95)) and younger (OR 0.91 (95% CI 0.76 to 1.10)) par-
ticipants was similar to the calculated odds ratio in the other 
studies, suggesting that, had they reported absolute numbers 
and been included in the meta-analysis, they would not have 
materially altered the findings.  
 
Discussion 
This systematic review has demonstrated the benefit of treat-
ment with a GLP-1 receptor agonist or an SGLT-2 inhibitor in 
older adults who were eligible for inclusion in these large ran-
domised controlled trials. In both cases the agents of interest 
were beneficial in older adults, with a smaller number of patients 
required to be treated in order to gain benefit. Indeed, in the 
case of SGLT-2 inhibitors, benefit was only seen in older adults 
whereas in younger populations no significant benefit was 
demonstrated. This is of particular relevance given the recent up-
date to the UK guidance for the management of older adults 
with diabetes, which emphasises the need to assess frailty in in-
dividuals and subsequently individualise the treatment options.3 
This stakeholder’s document highlighted the observation that 
weight loss in older adults has no proven benefit; indeed, it may 
exacerbate sarcopenia and thus have a detrimental impact on 
prognosis.21 As a result, the stakeholder’s position statement rec-
ommended caution in the use of agents that may promote 
weight loss. The current analysis suggests, however, that fitter 
older adults, who would have been eligible for inclusion in clin-
ical trials, would benefit from treatment with SGLT-2 inhibitors 
or GLP-1 analogues.  
It is important to acknowledge, however, that older clinical 
trial participants may not be truly representative of the general 
population. Indeed, the term ‘older adults’ can span more than 
35 years, from 65 years to centenarians, with some being robust 
in employment and independently active whilst others are in the 
terminal decline of multi-morbidity and frailty. The physiological 
differences attributable to frailty are substantial; however,          
current treatment strategies are based on extrapolation from the 
outcomes in chronologically matched patients.22 Frail older 
adults are rarely included in clinical trials, with exclusion criteria 
to recruitment such as polypharmacy, cognitive decline and        
multiple co-morbidities being common.23 For this reason, older 
adults included in cardiovascular outcome trials tend to be          
biologically healthier than the general older population.24 Even 
within these populations, trials of glycaemic control in older 
adults highlight an exaggerated ‘U-shaped’ curve with higher 
mortality at both low and higher HbA1c.25,26 To date there are 
very limited data on the optimal medication choices for frail 
older adults, and fewer still on the individualisation of care in 
those living with frailty.27 There is, however, a pressing need to 
explore such populations, given the significant impact that heart 
failure and stroke have on functional capacity in older adults. 
These complications of diabetes are significant contributors to 
frailty progression. The co-existence of heart failure and diabetes 
has a poorer prognosis than many cancers.28 An anticipated life 
expectancy of less than 7 years is a common exclusion criterion,29 
which would thereby exclude the patients with the most to gain 
in our analysis from the studies to evaluate their efficacy. 
This systematic review has highlighted the importance and 
potential benefits of using both GLP-1 agonists and SGLT-2          
inhibitors to reduce cardiovascular outcomes in older adults with 
type 2 diabetes. A key limitation is that only eight studies were 
eligible for inclusion. Therefore, it is very important that further 
research in this field is undertaken. It is also important to            
acknowledge that 3-point MACE does not represent the only 
outcome of interest for older adults living with diabetes. It is        
accepted that SGLT-2 inhibitors, as a class, improve outcomes 
for people living with heart failure. Hospitalisation from heart 
failure is important for older adults with diabetes; however, these 
outcomes are not stratified by age and thus were not included 
in this meta-analysis. In a population in whom weight loss is           
associated with frailty and poor cardiovascular outcomes, the 
absence of any adverse cardiovascular signals should be reassur-








• Unintentional weight loss is a poor prognostic 
indicator in older adults with type 2 diabetes 
• There has been concern regarding the use of 
sodium-glucose co-transporter-2 (SGLT-2) inhibitors 
and glucagon-like peptide-1 (GLP-1) receptor agonists 
in older adults because of their impact on weight 
• This systematic review and meta-analysis showed that 
major adverse cardiovascular events outcomes were 
reduced in older adults with both agents: in the case 
of GLP-1 receptor agonists, to a similar degree as seen 
in younger adults; in the case of SGLT-2 inhibitors, 
numerically superior to the benefit in younger 
populations 
• Whereas reassuring for robust older adults, this should 
not be extrapolated to frail patients without further 
research  
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Conclusions 
On the basis of these data, we would advocate the use of GLP-
1 analogues and SGLT-2 inhibitors in any older adult with mild 
or moderate frailty, particularly when the frailty is a function of 
cardiovascular disease itself. Further research is required to de-
termine whether the benefits are extended to older adults with 
severe frailty or patients at lower risk of cardiovascular events. 
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